Education
About Us
Working with TipRanks
Follow Us
Niagen Bioscience, Inc. (NAGE)
:NAGE
NAGE Stock Chart & Stats
$7.60
--
Market closed
$7.60
--
Day’s Range― - ―
52-Week Range$3.49 - $14.69
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.16M
Market Cap
$603.73M
Enterprise Value$1.19B
Total Cash (Recent Filing)$60.32M
Total Debt (Recent Filing)$3.29M
Price to Earnings (P/E)35.4
Beta0.87
Next Earnings
Nov 04, 2025EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding79,752,960
10 Day Avg. Volume948,589
30 Day Avg. Volume1,164,473
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.96
Enterprise Value/Revenue10.19
Enterprise Value/Gross Profit16.02
Enterprise Value/Ebitda65.44
Forecast
1Y Price Target
$15.55Price Target Upside104.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Financial PerformanceNiagen Bioscience's revenue and earnings have exceeded expectations, leading to an increased price target.
ProfitabilityNet income has increased from breakeven in the previous year to $3.6M, indicating sustained profitability.
Sales GrowthThe company's flagship nicotinamide riboside brand, TRU NIAGEN, delivered strong sales growth of 22%.
Bears Say
Geopolitical RiskRisks include, but are not limited to: slower-than-projected U.S. sales growth, unfavorable clinical data, adverse legal decisions, inability to achieve traction in ex-U.S. markets, and disruptions due to geopolitical risk factors.
Market CompetitionThe FDA decision that NMN can be used in supplements could lead to more NMN products and increased competition for Niagen Bioscience.
Niagen Bioscience News
NAGE FAQ
What was Niagen Bioscience, Inc.’s price range in the past 12 months?
Niagen Bioscience, Inc. lowest stock price was $3.49 and its highest was $14.69 in the past 12 months.
What is Niagen Bioscience, Inc.’s market cap?
Niagen Bioscience, Inc.’s market cap is $603.73M.
When is Niagen Bioscience, Inc.’s upcoming earnings report date?
Niagen Bioscience, Inc.’s upcoming earnings report date is Nov 04, 2025 which is in 6 days.
How were Niagen Bioscience, Inc.’s earnings last quarter?
Niagen Bioscience, Inc. released its earnings results on Aug 06, 2025. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.009 by $0.031.
Is Niagen Bioscience, Inc. overvalued?
According to Wall Street analysts Niagen Bioscience, Inc.’s price is currently Undervalued.
Does Niagen Bioscience, Inc. pay dividends?
Niagen Bioscience, Inc. does not currently pay dividends.
What is Niagen Bioscience, Inc.’s EPS estimate?
Niagen Bioscience, Inc.’s EPS estimate is 0.02.
How many shares outstanding does Niagen Bioscience, Inc. have?
Niagen Bioscience, Inc. has 79,752,960 shares outstanding.
What happened to Niagen Bioscience, Inc.’s price movement after its last earnings report?
Niagen Bioscience, Inc. reported an EPS of $0.04 in its last earnings report, beating expectations of $0.009. Following the earnings report the stock price went up 2.234%.
Which hedge fund is a major shareholder of Niagen Bioscience, Inc.?
Currently, no hedge funds are holding shares in NAGE
Niagen Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.55 (104.61% Upside)
$15.55 (104.61% Upside)
Blogger Sentiment
Bullish
NAGE Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 52.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 20.8%
Last 30 Days ▲ 20.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
119.02%
12-Months-Change
Fundamentals
Return on Equity
37.36%
Trailing 12-Months
Asset Growth
69.38%
Trailing 12-Months
Company Description
Niagen Bioscience, Inc.
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.
NAGE Company Deck
NAGE Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Niagen Bioscience presented a robust performance with significant revenue growth, increased net income, and cash generation. The expansion of Niagen Plus and a strengthened patent portfolio were key positive aspects. However, the company faces regulatory challenges and market misconceptions that require ongoing attention.View all NAGE earnings summariesNAGE Stock 12 Month Forecast
Average Price Target
$15.55
▲(104.61% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Kura Oncology
―
Vir Biotechnology
―
Fortrea Holdings Inc.
―
Septerna, Inc.
―
Ownership Overview
4.99% Insiders
8.86% Mutual Funds
0.76% Other Institutional Investors
77.31% Public Companies and Individual Investors
Options Prices
Currently, No data available
---